Inducing tumor-intrinsic innate immune response to break cancer immunotherapy resistance - Takeaways - MDSpire

Inducing tumor-intrinsic innate immune response to break cancer immunotherapy resistance

  • By

  • Jessica A. Blandino

  • Takahiko Murayama

  • July 3, 2026

  • 0 min

Share

  • 1

    Immune checkpoint blockade (ICB) therapy targeting PD-1/PD-L1 has transformed cancer treatment but responses are limited to a subset of patients.

  • 2

    Resistance to ICB is often due to an immunologically 'cold' tumor microenvironment (TME) with few infiltrating immune cells.

  • 3

    Inducing tumor-intrinsic innate immune responses through viral mimicry may convert 'cold' tumors to 'hot' and enhance ICB efficacy.

  • 4

    The TME's cellular and non-cellular components critically influence tumor sensitivity to ICB therapy.

  • 5

    Strategies to overcome ICB resistance include epigenetic therapies, agents affecting nucleic acid metabolism, and DNA damage inducers.

Original Source(s)

Inducing tumor-intrinsic innate immune response to break cancer immunotherapy resistance

  • by Jessica A. Blandino, Takahiko Murayama

  • July 3, 2026

Related Content

A review on in-silico analysis of immune cell trafficking and interactions with the tumour microenvironment

Prediction of histological grading in ductal carcinoma in situ based on mammographic signs and clinical information using machine learning models

Detection of cancer recurrence from Thai-English electronic medical records using sentence embeddings